InvestorsHub Logo
Post# of 181881
Next 10
Followers 23
Posts 4591
Boards Moderated 0
Alias Born 07/15/2012

Re: None

Wednesday, 02/07/2024 1:17:47 PM

Wednesday, February 07, 2024 1:17:47 PM

Post# of 181881
Vivos Inc. has researched and developed patents related to the RadioGel™ device technology for use in high-dose radiation therapy. These patents have established our independence and no longer relying on external sources.

Vivos may have made, use and market RadioGel™ as a medical device. Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble yttrium-90 particles and the polymer gel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a reasonable cost.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDGL News